Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anjana Grandhi

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
BMC Bioinformatics|February 27, 2016
A multiple testing procedure for multi-dimensional pairwise comparisons with application to gene expression studiesAnjana Grandhi, Wenge Guo, Shyamal D Peddada
The Pediatric Infectious Disease Journal|February 7, 2018
Randomized Multicenter Study Comparing Safety and Efficacy of Daptomycin Versus Standard-of-care in Pediatric Patients With Staphylococcal BacteremiaAntonio C Arrieta, John S Bradley, Myra W Popejoy, et al.
Clinical Drug Investigation|September 7, 2023
Pharmacokinetic and Exposure Response Analysis of the Double-Blind Randomized Study of Posaconazole and Voriconazole for Treatment of Invasive AspergillosisJohan A Maertens, Galia Rahav, Dong-Gun Lee, et al.
The Pediatric Infectious Disease Journal|July 9, 2020
Daptomycin for Pediatric Gram-Positive Acute Hematogenous OsteomyelitisJohn S Bradley, Antonio C Arrieta, Valeri A Digtyar, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|August 16, 2022
Brief Report: Efficacy and Safety of Oral Islatravir Once Daily in Combination With Doravirine Through 96 Weeks for Treatment-Naive Adults With HIV-1 Infection Receiving Initial Treatment With Islatravir, Doravirine, and LamivudineJean-Michel Molina, Yazdan Yazdanpanah, Alejandro Afani Saud, et al.
The Journal of Infectious Diseases|May 29, 2026
Switching to Daily Doravirine/Islatravir (100/0.25 mg) Maintains Viral Suppression Through Week 48 Despite Baseline Non-Nucleoside Reverse Transcriptase Inhibitor Resistance-Associated Mutations or M184I/V in Proviral DNATracy L Diamond, Anjana Grandhi, Monica Fuszard, et al.
The Lancet. HIV|May 17, 2021
Islatravir in combination with doravirine for treatment-naive adults with HIV-1 infection receiving initial treatment with islatravir, doravirine, and lamivudine: a phase 2b, randomised, double-blind, dose-ranging trialJean-Michel Molina, Yazdan Yazdanpanah, Alejandro Afani Saud, et al.
The Lancet. HIV|May 11, 2024
Switch to fixed-dose doravirine (100 mg) with islatravir (0·75 mg) once daily in virologically suppressed adults with HIV-1 on antiretroviral therapy: 48-week results of a phase 3, randomised, open-label, non-inferiority trialJean-Michel Molina, Giuliano Rizzardini, Catherine Orrell, et al.
Lancet (London, England)|February 7, 2026
Switch to fixed-dose doravirine (100 mg) and islatravir (0·25 mg) once daily in virologically suppressed adults with HIV-1 on oral antiretroviral therapy: 48-week results of a phase 3, multicentre, randomised, open-label, non-inferiority trialChloe Orkin, Rosie Mngqibisa, Juan Diego Velez, et al.
Lancet (London, England)|February 7, 2021
Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: a phase 3, randomised, controlled, non-inferiority trialJohan A Maertens, Galia Rahav, Dong-Gun Lee, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
BMC Bioinformatics|February 27, 2016
A multiple testing procedure for multi-dimensional pairwise comparisons with application to gene expression studiesAnjana Grandhi, Wenge Guo, Shyamal D Peddada
The Pediatric Infectious Disease Journal|February 7, 2018
Randomized Multicenter Study Comparing Safety and Efficacy of Daptomycin Versus Standard-of-care in Pediatric Patients With Staphylococcal BacteremiaAntonio C Arrieta, John S Bradley, Myra W Popejoy, et al.
Clinical Drug Investigation|September 7, 2023
Pharmacokinetic and Exposure Response Analysis of the Double-Blind Randomized Study of Posaconazole and Voriconazole for Treatment of Invasive AspergillosisJohan A Maertens, Galia Rahav, Dong-Gun Lee, et al.
The Pediatric Infectious Disease Journal|July 9, 2020
Daptomycin for Pediatric Gram-Positive Acute Hematogenous OsteomyelitisJohn S Bradley, Antonio C Arrieta, Valeri A Digtyar, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|August 16, 2022
Brief Report: Efficacy and Safety of Oral Islatravir Once Daily in Combination With Doravirine Through 96 Weeks for Treatment-Naive Adults With HIV-1 Infection Receiving Initial Treatment With Islatravir, Doravirine, and LamivudineJean-Michel Molina, Yazdan Yazdanpanah, Alejandro Afani Saud, et al.
The Journal of Infectious Diseases|May 29, 2026
Switching to Daily Doravirine/Islatravir (100/0.25 mg) Maintains Viral Suppression Through Week 48 Despite Baseline Non-Nucleoside Reverse Transcriptase Inhibitor Resistance-Associated Mutations or M184I/V in Proviral DNATracy L Diamond, Anjana Grandhi, Monica Fuszard, et al.
The Lancet. HIV|May 17, 2021
Islatravir in combination with doravirine for treatment-naive adults with HIV-1 infection receiving initial treatment with islatravir, doravirine, and lamivudine: a phase 2b, randomised, double-blind, dose-ranging trialJean-Michel Molina, Yazdan Yazdanpanah, Alejandro Afani Saud, et al.
The Lancet. HIV|May 11, 2024
Switch to fixed-dose doravirine (100 mg) with islatravir (0·75 mg) once daily in virologically suppressed adults with HIV-1 on antiretroviral therapy: 48-week results of a phase 3, randomised, open-label, non-inferiority trialJean-Michel Molina, Giuliano Rizzardini, Catherine Orrell, et al.
Lancet (London, England)|February 7, 2026
Switch to fixed-dose doravirine (100 mg) and islatravir (0·25 mg) once daily in virologically suppressed adults with HIV-1 on oral antiretroviral therapy: 48-week results of a phase 3, multicentre, randomised, open-label, non-inferiority trialChloe Orkin, Rosie Mngqibisa, Juan Diego Velez, et al.
Lancet (London, England)|February 7, 2021
Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: a phase 3, randomised, controlled, non-inferiority trialJohan A Maertens, Galia Rahav, Dong-Gun Lee, et al.
Pageof 2